[Home]  [Headlines]  [Latest Articles]  [Latest Comments]  [Post]  [Mail]  [Sign-in]  [Setup]  [Help]  [Register] 

Antiwar Activists Chant ‘Death to America’ at Event Featuring Chicago Alderman

Vibe Shift

A stream that makes the pleasant Rain sound.

Older Men - Keep One Foot In The Dark Ages

When You Really Want to Meet the Diversity Requirements

CERN to test world's most powerful particle accelerator during April's solar eclipse

Utopian Visionaries Who Won’t Leave People Alone

No - no - no Ain'T going To get away with iT

Pete Buttplug's Butt Plugger Trying to Turn Kids into Faggots

Mark Levin: I'm sick and tired of these attacks

Questioning the Big Bang

James Webb Data Contradicts the Big Bang

Pssst! Don't tell the creationists, but scientists don't have a clue how life began

A fine romance: how humans and chimps just couldn't let go

Early humans had sex with chimps

O’Keefe dons bulletproof vest to extract undercover journalist from NGO camp.

Biblical Contradictions (Alleged)

Catholic Church Praising Lucifer

Raising the Knife

One Of The HARDEST Videos I Had To Make..

Houthi rebels' attack severely damages a Belize-flagged ship in key strait leading to the Red Sea (British Ship)

Chinese Illegal Alien. I'm here for the moneuy

Red Tides Plague Gulf Beaches

Tucker Carlson calls out Nikki Haley, Ben Shapiro, and every other person calling for war:

{Are there 7 Deadly Sins?} I’ve heard people refer to the “7 Deadly Sins,” but I haven’t been able to find that sort of list in Scripture.

Abomination of Desolation | THEORY, BIBLE STUDY

Bible Help

Libertysflame Database Updated

Crush EVERYONE with the Alien Gambit!

Vladimir Putin tells Tucker Carlson US should stop arming Ukraine to end war

Putin hints Moscow and Washington in back-channel talks in revealing Tucker Carlson interview

Trump accuses Fulton County DA Fani Willis of lying in court response to Roman's motion

Mandatory anti-white racism at Disney.

Iceland Volcano Erupts For Third Time In 2 Months, State Of Emergency Declared

Tucker Carlson Interview with Vladamir Putin

How will Ar Mageddon / WW III End?

What on EARTH is going on in Acts 16:11? New Discovery!

2023 Hottest in over 120 Million Years

2024 and beyond in prophecy

Questions

This Speech Just Broke the Internet

This AMAZING Math Formula Will Teach You About God!

The GOSPEL of the ALIENS | Fallen Angels | Giants | Anunnaki

The IMAGE of the BEAST Revealed (REV 13) - WARNING: Not for Everyone

WEF Calls for AI to Replace Voters: ‘Why Do We Need Elections?’

The OCCULT Burger king EXPOSED

PANERA BREAD Antichrist message EXPOSED

The OCCULT Cheesecake Factory EXPOSED

Satanist And Witches Encounter The Cross

History and Beliefs of the Waldensians


Status: Not Logged In; Sign In

Health/Medical
See other Health/Medical Articles

Title: Could this be the end of Alzheimer's? Revolutionary drug 'may stop the disease from ever developing'
Source: Daily Mail Online
URL Source: http://www.dailymail.co.uk/health/a ... lear-toxic-proteins-brain.html
Published: Aug 31, 2016
Author: Fiona MacRae
Post Date: 2016-08-31 21:12:30 by cranky
Keywords: None
Views: 4936
Comments: 27

  • Aducanumab is designed to target the underlying damage to the brain
  • Works by targeting the hallmark tangle of proteins in Alzheimer's patients
  • Study showed those who took drug had reduced build up after a year
  • Experts hailed the findings as 'game-changing' and 'unprecedented'

A revolutionary drug that could stop people from ever developing Alzheimer’s disease has been unveiled by scientists.

Trials have produced ‘unprecedented’ results and the medicine has been hailed as a potential game-changer in the fight against the cruel disease.

In future, healthy pensioners could be prescribed the drug to ward off dementia, in much the same way as statins are given today to those at risk of heart attacks.

One British expert described the drug, which is about to be tested in hospitals around the UK, as the best yet, others called it ‘ingenious’ work with ‘tantalising’ results.

And a US doctor hailed it as the best news in his 25-year career.

The revolutionary drug, aducanumab, could stop people from developing Alzheimer’s disease

The revolutionary drug, aducanumab, could stop people from developing Alzheimer’s disease

Alzheimer’s and other forms of dementia affect some 850,000 Britons, with one new case every three minutes.

Existing drugs are of limited benefit and despite billions of pounds being spent on research, no new medicines have hit the market in more than a decade.

While current therapies ease the symptoms, aducanumab tackles the underlying damage in the brain, raising hopes it will be the first to alter the course of the disease.

It contains an antibody that homes in on amyloid, the protein that clogs the brain in Alzheimer's, poisoning and killing the cells.

In preliminary trials, involving 165 people in the early stages of the disease, the Swiss-designed drug triggered the removal of amyloid from the brain.

And in men and women given a monthly infusion of a high dose of the drug, the amyloid all but vanished after a year.

This ‘unprecedented’ effect was deemed so significant that the results have been published in Nature the world’s top science journal.

The new drug has been found to get rid of clumps of the amyloid protein are a hallmark of Alzheimer's and are thought to be harmful to brain cells

The new drug has been found to get rid of clumps of the amyloid protein are a hallmark of Alzheimer's and are thought to be harmful to brain cells

WHAT THE EXPERTS SAY

Professor Richard Morris, of Edinburgh University

The importance of this first step cannot be understated

Professor David Allsop, of the University of Lancaster

These findings could be a “game-changer”

Dr James Pickett, head of research at the Alzheimer’s Society

These results are the most detailed and promising that we’ve seen for a drug that aims to modify the underlying causes of Alzheimer’s disease.

Dr David Reynolds, chief scientific officer of Alzheimer’s Research UK

These results provide tantalising evidence that a new class of drug to treat the disease may be on the horizon.

Professor John Hardy, University College London

These new data are tantalising

Professor Stephen Salloway (CORR), of the Butler Hospital in Rhode Island

This is the best news I’ve had in my 25 years of doing Alzheimer’s research.

Professor Roger Nitsch (CORR), of the University of Zurich

The effect of this drug is unprecedented.

US researcher Stephen Salloway, of the Butler Hospital in Rhode Island said: ‘This is the best news I’ve had in my 25 years of doing Alzheimer’s research.

‘It brings new hope to the patients and families most affected by this disease.’

Even more excitingly, the drug seemed to halt the disease.

Men and women who weren’t treated experienced steady declines in memory and day to day functioning, such as the ability to cook for themselves or take out the rubbish but those given high doses of the drug stopped getting any worse after just six months of treatment.

The number of people tested was too small to be sure the drug can really stop the disease in its tracks and a larger trial, involving 2,700 people in the early stage of Alzheimer’s, is underway.

Hospitals and clinics in eight British cities, including London, Newcastle, Glasgow, Edinburgh and Dundee are taking part and are looking for patients.

The trial is due to finish in 2020 and, if aducanumab is deemed safe and effective, it could be available shortly afterwards.

However, there are several hurdles to overcome.

Drugs that have seemed promising when given to small groups of people can fail spectacularly when tested on large numbers.

Plus, aducanumab can cause a worrying side-effect, in which fluid accumulates in the brain, raising the risk of strokes.

Challenges include finding a dose that is high enough to work but not so powerful that it does damage.

Other amyloid-busting antibodies have been tried before.

But aducanumab, which is based on antibodies naturally made by pensioners who seem to be immune to Alzheimer’s, is said to be the best yet.

It is thought it is better at getting into the brain and more likely to zero in on the damaging amyloid than previous drugs.

Aducanumab is a type of therapy called an antibody, designed to target the amyloid protein in patientsin the early stages of Alzheimer's

Aducanumab is a type of therapy called an antibody, designed to target the amyloid protein in patientsin the early stages of Alzheimer's

In future, aducanumab, which was originally developed at the University of Zurich, could be given to seemingly healthy pensioners, in a bid to keep them going on to develop Alzheimer’s.

People could be given brain scans in their 60s and 70s and those thought to be at risk of dementia given the drug.

Today, some 15 per cent of 65-year-olds have a build-up of amyloid but are still symptom-free.

Alfred Sandrock, of Biogen, the US drug company developing the drug, said: ‘I could imagine a time when we would treat people before they have symptoms.

‘We do that now, for example we treat people with high cholesterol before they get heart disease because we would like to prevent heart disease.’

Experts cautioned that it is too early to be certain that aducanumab works. However, the early results have caused huge excitement.

Richard Morris, a professor of neuroscience at Edinburgh University, said: ‘The importance of this first step cannot be understated.

‘Let’s keep our fingers crossed for success in the next steps.’

Professor David Allsop, of the University of Lancaster, said: ‘These findings could be a “game-changer” if the effects on memory decline could be confirmed.’

Dr James Pickett, head of research at the Alzheimer’s Society, said: ‘These results are the most detailed and promising that we’ve seen for a drug that aims to modify the underlying causes of Alzheimer’s disease.’

Dr David Reynolds, chief scientific officer of Alzheimer’s Research UK, said: ‘These results provide tantalising evidence that a new class of drug to treat the disease may be on the horizon.

‘It has been over a decade since the last drug was licensed for use in people with Alzheimer’s and there are currently no treatments able to stop the disease in its tracks.’ (3 images)

Post Comment   Private Reply   Ignore Thread  


TopPage UpFull ThreadPage DownBottom/Latest

#1. To: cranky (#0)

However, there are several hurdles to overcome.

Price will probably be one.

I do not go to church every time the doors are opened, but I love Jesus Christ. I am only human and fail Him daily. I believe Jesus is the Son of God, was born of a virgin, was crucified on a cross, died for my sins and rose from the dead and that He loves us dearly, and is faithful to forgive us of our sins. But He says that if you deny me in front of your friends I will deny you in front of my Father. Can I get an Amen!

U don't know me  posted on  2016-08-31   22:01:03 ET  Reply   Trace   Private Reply  


#2. To: cranky (#0)

In preliminary trials, involving 165 people in the early stages of the disease, the Swiss-designed drug triggered the removal of amyloid from the brain.

So does THC, by the by.

A government strong enough to impose your standards is strong enough to ban them.

ConservingFreedom  posted on  2016-08-31   22:26:33 ET  Reply   Trace   Private Reply  


#3. To: ConservingFreedom, cranky (#2)

In preliminary trials, involving 165 people in the early stages of the disease, the Swiss-designed drug triggered the removal of amyloid from the brain.

So does THC, by the by.

DEA, Docket DEA-427, Denial to Petition To Initiate Proceedings To Reschedle Marijuana, Fed. Reg. Vol. 81, No. 156 (12 August 2016) page 53776

Cardiovascular and Autonomic Effects

Single smoked or oral doses of delta9-THC produce tachycardia and may increase blood pressure (Capriotti et al., 1988; Benowitz and Jones, 1975). Some evidence associates the tachycardia produced by delta9-THC with excitation of the sympathetic and depression of the parasympathetic nervous systems (Malinowska et al., 2012). During chronic marijuana ingestion, a tolerance to tachycardia develops (Malinowska et al., 2012).

However, prolonged delta9-THC ingestion produces bradycardia and hypotension (Benowitz and Jones, 1975). Plant-derived cannabinoids and endocannabinoids elicit hypotension and bradycardia via activation of peripherally-located CB1 receptors (Wagner et al., 1998). Specifically, the mechanism of this effect is through presynaptic CB1 receptor-mediated inhibition of norepinephrine release from peripheral sympathetic nerve terminals, with possible additional direct vasodilation via activation of vascular cannabinoid receptors (Pacher et al., 2006). In humans, tolerance can develop to orthostatic hypotension (Jones, 2002; Sidney, 2002) possibly related to plasma volume expansion, but tolerance does not develop to the supine hypotensive effects (Benowitz and Jones, 1975). Additionally, electrocardiographic changes are minimal, even after large cumulative doses of delta9-THC are administered. (Benowitz and Jones, 1975).

Marijuana smoking by individuals, particularly those with some degree of coronary artery or cerebrovascular disease, poses risks such as increased cardiac work, catecholamines and carboxyhemoglobin, myocardial infarction, and postural hypotension (Benowitz and Jones, 1981; Hollister, 1988; Mittleman et al., 2001; Malinowska et al., 2012).

nolu chan  posted on  2016-08-31   23:54:40 ET  Reply   Trace   Private Reply  


#4. To: nolu chan (#3) (Edited)

Cardiovascular and Autonomic Effects

Single smoked or oral doses of delta9-THC produce tachycardia and may increase blood pressure (Capriotti et al., 1988; Benowitz and Jones, 1975). Some evidence associates the tachycardia produced by delta9-THC with excitation of the sympathetic and depression of the parasympathetic nervous systems (Malinowska et al., 2012). During chronic marijuana ingestion, a tolerance to tachycardia develops (Malinowska et al., 2012).

However, prolonged delta9-THC ingestion produces bradycardia and hypotension (Benowitz and Jones, 1975). Plant-derived cannabinoids and endocannabinoids elicit hypotension and bradycardia via activation of peripherally-located CB1 receptors (Wagner et al., 1998). Specifically, the mechanism of this effect is through presynaptic CB1 receptor-mediated inhibition of norepinephrine release from peripheral sympathetic nerve terminals, with possible additional direct vasodilation via activation of vascular cannabinoid receptors (Pacher et al., 2006). In humans, tolerance can develop to orthostatic hypotension (Jones, 2002; Sidney, 2002) possibly related to plasma volume expansion, but tolerance does not develop to the supine hypotensive effects (Benowitz and Jones, 1975). Additionally, electrocardiographic changes are minimal, even after large cumulative doses of delta9-THC are administered. (Benowitz and Jones, 1975).

Marijuana smoking by individuals, particularly those with some degree of coronary artery or cerebrovascular disease, poses risks such as increased cardiac work, catecholamines and carboxyhemoglobin, myocardial infarction, and postural hypotension (Benowitz and Jones, 1981; Hollister, 1988; Mittleman et al., 2001; Malinowska et al., 2012).

Well, if the gubmint sez it, it must be so.

Because bureaucrats are never wrong.

cranky  posted on  2016-09-01   7:16:43 ET  Reply   Trace   Private Reply  


#5. To: nolu chan (#3)

So THC has negative side effects - does aducanumab have none? Ought we ban all medicines with negative side effects?

A government strong enough to impose your standards is strong enough to ban them.

ConservingFreedom  posted on  2016-09-01   11:21:41 ET  Reply   Trace   Private Reply  


#6. To: cranky (#4)

Well, if the gubmint sez it, it must be so.

Because bureaucrats are never wrong.

Actually, is is extensively footnoted to scientific studies.

nolu chan  posted on  2016-09-02   18:20:36 ET  Reply   Trace   Private Reply  


#7. To: ConservingFreedom (#5)

So THC has negative side effects - does aducanumab have none? Ought we ban all medicines with negative side effects?

One of those side effects being myocardial infarction.

Aducanumab is in the clinical trial stage.

Test marijuana, submit your results, and get approved.

For marijuana, note that "[c]urrently, no published studies conducted with marijuana meet the criteria of an adequate and well-congroled efficacy study." FR 53780.

Fed. Reg. 53780, August 12, 2016

The PubMed search yielded a total of 566 abstracts of scientific articles. Of these abstracts, a full-text review was conducted with 85 papers to assess eligibility. Of the studies identified through the search of the references and the 566 abstracts from the PubMed search, only 11 studies met all the criteria for selection (Abrams et al., 2007; Corey-Bloom et al., 2012; Crawford and Merritt, 1979; Ellis et al., 2009; Haney et al., 2005; Haney et al., 2007; Merritt et al., 1980; Tashkin et al., 1974; Ware et al., 2010; Wilsey et al., 2008; Wilsey et al., 2013). These 11 studies were published between 1974 and 2013. Ten of these studies were conducted in the United States and one study was conducted in Canada. The identified studies examine the effects of smoked and vaporized marijuana for the indications of chronic neuropathic pain, spasticity related to Multiple Sclerosis (MS), appetite stimulation in human immunodeficiency virus (HIV) patients, glaucoma, and asthma. All studies used adult subjects.

The 11 identified studies were individually evaluated to determine if they successfully meet accepted scientific standards. Specifically, they were evaluated on study design including subject selection criteria, sample size, blinding techniques, dosing paradigms, outcome measures, and the statistical analysis of the results. The analysis relied on published studies, thus information available about protocols, procedures, and results were limited to documents published and widely available in the public domain. The review found that all 11 studies that examined effects of inhaled marijuana do not currently prove efficacy of marijuana in any therapeutic indication based on a number of limitations in their study design; however, they may be considered proof of concept studies. Proof of concept studies provide preliminary evidence on a proposed hypothesis involving a drug’s effect. For drugs under development, the effect often relates to a short-term clinical outcome being investigated. Proof of concept studies often serve as the link between preclinical studies and dose ranging clinical studies. Thus, proof of concept studies generally are not sufficient to prove efficacy of a drug because they provide only preliminary information about the effects of a drug.

nolu chan  posted on  2016-09-02   18:40:24 ET  Reply   Trace   Private Reply  


#8. To: nolu chan (#7)

Test marijuana, submit your results, and get approved.

I say, leave medical decisions to doctors in consultation with patients.

A government strong enough to impose your standards is strong enough to ban them.

ConservingFreedom  posted on  2016-09-02   20:39:42 ET  Reply   Trace   Private Reply  


#9. To: ConservingFreedom (#8)

I say, leave medical decisions to doctors in consultation with patients.

I say, that's not what the law says. If you dislike the law, work to change the law.

As for doctors, they have already proven that they will prescribe marijuana for patients they have either not fully evaluated, or whom they have not met at all.

nolu chan  posted on  2016-09-02   22:44:11 ET  Reply   Trace   Private Reply  


#10. To: nolu chan (#9)

If you dislike the law, work to change the law.

Will I have your support?

As for doctors, they have already proven that they will prescribe marijuana for patients they have either not fully evaluated, or whom they have not met at all.

Doctors have misprescribed opiate painkillers - shall we ban those too?

A government strong enough to impose your standards is strong enough to ban them.

ConservingFreedom  posted on  2016-09-02   22:59:06 ET  Reply   Trace   Private Reply  


#11. To: ConservingFreedom, nolu spam, Y'ALL (#10)

Doctors have misprescribed opiate painkillers - shall we ban those too?

It'll be interesting to see how nolu sham answers that...

tpaine  posted on  2016-09-02   23:13:29 ET  Reply   Trace   Private Reply  


#12. To: ConservingFreedom (#10)

If you dislike the law, work to change the law.

Will I have your support?

I will support your efforts to meet the legal requirements. The only lawful possession is for federally authorized research. Other than that, marijuana (including so-called medical marijuana) is illegal in any quantity in all 52 federal jurisdictions, which includes all 50 states.

If you can get the federal law changed, I will acknowledge your achievement if I live that long. Citizen proposals that become state laws have no legal effect if they conflict with federal law.

A big opponent may be the alcohol lobby and the tax man. Think of what legal pot would do to alcohol sales and taxes.

If you can change the law, and make marijuana legal like alcohol, be prepared for what happened to alcohol when prohibition ended. No one will be allowed to grow and sell to individuals or retailers. All sales will go to licensed distributors. That was how government weeded (extra credit for word play) out mobsters from legitimate businesses. A very significant federal marijuana tax will be reinstated. The tax only stopped when marijuana was declared illegal. There is no taxing of a substance that is illegal to possess.

The relatively small pot farms will be inundated with regulations, making pot cultivation expensive. They will need paper shufflers and accountants. The costs of doing business will force them to succumb to big farming. Give it time and you will have Monsanto pot. Plan on government taxing at a rate to maintain revenue.

I do not personally care if you smoke so much pot that Willie Nelson gets high off your secondary smoke. That would not extend to driving stoned on a public road, or running about with gun while seriously impaired.

As for getting approval of marijuana for medical use, the first major hurdle to get over is:

i. the drug’s chemistry must be known and reproducible

"The substance’s chemistry must be scientifically established to permit it to be reproduced into dosages which can be standardized. The listing of the substance in a current edition of one of the official compendia, as defined by section 201 G) of the Food, Drug and Cosmetic Act, 21 U.S.C. 321G), is sufficient to meet this requirement."

See Fed. Reg. 81-156, 12 Aug 2016 at 53779.

As for doctors, they have already proven that they will prescribe marijuana for patients they have either not fully evaluated, or whom they have not met at all.

Doctors have misprescribed opiate painkillers - shall we ban those too?

We should take the licenses of those doctors and put them in prison. They have committed crimes and created drug addicts.

Usually, they at least see the patient. Pot scrips have been written for patients never seen, much less evaluated. The substance is illegal, the scrip is illegal, the doctor is committing a criminal act, and the patient may wind up prosecuted for unlawful possession.

Many doctors have misprescribed antibiotics for the common cold. About all they accomplish is to facilitate growing superbugs. It should be stopped, but it is not an argument for or against marijuana.

nolu chan  posted on  2016-09-03   18:45:43 ET  Reply   Trace   Private Reply  


#13. To: nolu chan (#12)

"Will I have your support?"

If you can get the federal law changed, I will acknowledge your achievement if I live that long.

Not what I asked. Will you answer the question I asked?

"Doctors have misprescribed opiate painkillers - shall we ban those too?"

We should take the licenses of those doctors and put them in prison. They have committed crimes and created drug addicts.

Again, not what I asked. Will you answer the question I asked?

it is not an argument for or against marijuana.

I never said nor implied it was; but if misprescribing antibiotics or opiate painkillers is not an argument for banning those drugs, then misprescribing marijuana is not an argument for banning that drug.

A government strong enough to impose your standards is strong enough to ban them.

ConservingFreedom  posted on  2016-09-03   19:09:02 ET  Reply   Trace   Private Reply  


#14. To: tpaine (#11)

how nolu sham answers that

He didn't ... while trying to look like he did.

A government strong enough to impose your standards is strong enough to ban them.

ConservingFreedom  posted on  2016-09-03   19:17:44 ET  Reply   Trace   Private Reply  


#15. To: ConservingFreedom (#13)

Will I have your support?

I will support your efforts to meet the legal requirements.

That's was your answer. If you want to select something from another paragraph down, that is your choice.

if misprescribing antibiotics or opiate painkillers is not an argument for banning those drugs, then misprescribing marijuana is not an argument for banning that drug.

Medicines are legal, marijuana is not. Misprescribing legal opiate painkillers does nothing to make marijuana legal. Your bullshit is just bullshit.

nolu chan  posted on  2016-09-03   20:18:55 ET  Reply   Trace   Private Reply  


#16. To: nolu chan (#15)

If you dislike the law, work to change the law.

"Will I have your support?"

I will support your efforts to meet the legal requirements.

Still not what I asked.

"if misprescribing antibiotics or opiate painkillers is not an argument for banning those drugs, then misprescribing marijuana is not an argument for banning that drug."

Medicines are legal

According to your argument, since they're misprescribed they shouldn't be.

Misprescribing legal opiate painkillers does nothing to make marijuana legal.

I never said nor implied it did. Your bullshit is just bullshit.

A government strong enough to impose your standards is strong enough to ban them.

ConservingFreedom  posted on  2016-09-03   20:23:31 ET  Reply   Trace   Private Reply  


#17. To: nolu chan, conserving freedom (#15)

"Doctors have misprescribed opiate painkillers - shall we ban those too?" ---- if misprescribing antibiotics or opiate painkillers is not an argument for banning those drugs, then misprescribing marijuana is not an argument for banning that drug. -- C.F.

nolu sham --- Medicines are legal, marijuana is not. Misprescribing legal opiate painkillers does nothing to make marijuana legal.

Incredibly silly circular reasoning.

--- This clown pretends to be a legal expert, posting page after page of court opinions, yet he reasons like a grade school dropout. -- Pitiful display.

tpaine  posted on  2016-09-03   23:33:14 ET  Reply   Trace   Private Reply  


#18. To: ConservingFreedom (#2)

So does THC, by the by.

It cannot be privatized. Look up rent seeking.

A Pole  posted on  2016-09-04   12:57:25 ET  Reply   Trace   Private Reply  


#19. To: A Pole (#18)

"So does THC, by the by."

It cannot be privatized. Look up rent seeking.

Oh, I know very well why rent-seeking Big Pharma is against medical marijuana.

A government strong enough to impose your standards is strong enough to ban them.

ConservingFreedom  posted on  2016-09-04   15:25:00 ET  Reply   Trace   Private Reply  


#20. To: tpaine (#17)

This clown pretends to be a legal expert, posting page after page of court opinions, yet he reasons like a grade school dropout.

That's nolu spam/sham in a nutshell. Though maybe not so much "dropout" as "dropped on his head."

A government strong enough to impose your standards is strong enough to ban them.

ConservingFreedom  posted on  2016-09-04   15:26:29 ET  Reply   Trace   Private Reply  


#21. To: ConservingFreedom (#20)

Your pretended concern about medical marijuana is as believeable as the stories being spun by your heroine, Hillary.

As for getting approval of marijuana for medical use, the first major hurdle to get over is:

i. the drug’s chemistry must be known and reproducible

"The substance’s chemistry must be scientifically established to permit it to be reproduced into dosages which can be standardized. The listing of the substance in a current edition of one of the official compendia, as defined by section 201 G) of the Food, Drug and Cosmetic Act, 21 U.S.C. 321G), is sufficient to meet this requirement."

See Fed. Reg. 81-156, 12 Aug 2016 at 53779.

I see how fast you have run from that. Of course, another hurdle will be the delivery system.

We do not ban drugs that have met all the requirements to be legally prescribed because a doctor misbehaves.

We do not authorize the dispensing of illegal drugs that have not met the requirements to be legally prescribed because you want to get high.

When you make an effort to create medical marijuana, you may be taken seriously. In the meantime, you might as well drop the bullshit and admit you are using the term medical marijuana just to further your cause of recreational marijuana. You want a legal high. Good luck with that.

nolu chan  posted on  2016-09-04   19:40:07 ET  Reply   Trace   Private Reply  


#22. To: nolu chan (#21)

We do not ban drugs that have met all the requirements to be legally prescribed because a doctor misbehaves.

So the business about how some doctors misprescribe marijuana was a red herring on your part.

A government strong enough to impose your standards is strong enough to ban them.

ConservingFreedom  posted on  2016-09-04   21:48:49 ET  Reply   Trace   Private Reply  


#23. To: ConservingFreedom (#22)

So the business about how some doctors misprescribe marijuana was a red herring on your part.

No. It was pointing out that your crying about medicine for sick people is a crock of shit and always has been. All of a sudden, everybody has a debilitating condition that calls for marijuana which you apparently believe has been proven to cure all maladies known to man.

There is no such thing as misprescribing marijuana. It is illegal to possess, in any qualtity, pursuant to federal law. It is a crime in all 52 federal jurisdictions, which includes all 50 states.

It is your incessant bullshit about medical and medicine that is the red herring. Marijuana has never met the standards for a prescription drug product. Marijuana is not medicine.

You will do just about anything to change the subject from the requirements for medicine approval.

You can always try addressing the first element required by established case law. Or not. You can always just continue to act on your supreme belief that you can baffle people with your bullshit.

In general, a drug may have a ‘‘currently accepted medical use’’ in treatment in the United States if the drug meets a five-part test. Established case law (Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131, 1135 (D.C. Cir. 1994)) upheld the Administrator of DEA’s application of the five-part test to determine whether a drug has a ‘‘currently accepted medical use.’’ The following describes the five elements that characterize ‘‘currently accepted medical use’’ for a drug:

i. the drug’s chemistry must be known and reproducible

‘‘The substance’s chemistry must be scientifically established to permit it to be reproduced into dosages which can be standardized. The listing of the substance in a current edition of one of the official compendia, as defined by section 201 G) of the Food, Drug and Cosmetic Act, 21 U.S.C. 321G), is sufficient to meet this requirement.’’

81 FR 53779.

nolu chan  posted on  2016-09-05   0:24:24 ET  Reply   Trace   Private Reply  


#24. To: nolu chan (#23)

All of a sudden, everybody has a debilitating condition that calls for marijuana which you apparently believe has been proven to cure all maladies known to man.

Beat those straw men.

A government strong enough to impose your standards is strong enough to ban them.

ConservingFreedom  posted on  2016-09-05   0:25:49 ET  Reply   Trace   Private Reply  


#25. To: ConservingFreedom (#24)

Beat those straw men.

You will do just about anything to change the subject from the requirements for medicine approval. Marijuana is illegal. It is not medicine.

You can always try addressing the first element required by established case law. Or not. You can always just continue to act on your supreme belief that you can baffle people with your bullshit.

In general, a drug may have a ‘‘currently accepted medical use’’ in treatment in the United States if the drug meets a five-part test. Established case law (Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131, 1135 (D.C. Cir. 1994)) upheld the Administrator of DEA’s application of the five-part test to determine whether a drug has a ‘‘currently accepted medical use.’’ The following describes the five elements that characterize ‘‘currently accepted medical use’’ for a drug:

i. the drug’s chemistry must be known and reproducible

‘‘The substance’s chemistry must be scientifically established to permit it to be reproduced into dosages which can be standardized. The listing of the substance in a current edition of one of the official compendia, as defined by section 201 G) of the Food, Drug and Cosmetic Act, 21 U.S.C. 321G), is sufficient to meet this requirement.’’

81 FR 53779.

That's one of five, and marijuana fails all five.

nolu chan  posted on  2016-09-05   1:23:48 ET  Reply   Trace   Private Reply  


#26. To: nolu chan (#25)

You will do just about anything to change the subject

Quoting your words is not changing the subject, fool.

A government strong enough to impose your standards is strong enough to ban them.

ConservingFreedom  posted on  2016-09-05   8:42:16 ET  Reply   Trace   Private Reply  


#27. To: ConservingFreedom (#26)

DEA, 81 FR 53779-53781, August 12, 2016

Status of Research Into the Medical Uses for Marijuana

State-level public initiatives, including laws and referenda in support of the medical use of marijuana, have generated interest in the medical community and the need for high quality clinical investigation as well as comprehensive safety and effectiveness data. In order to address the need for high quality clinical investigations, the state of California established the Center for Medicinal Cannabis Research (CMCR, www.cmcr.ucsd.edu) in 2000 ''in response to scientific evidence for therapeutic possibilities of cannabis[9] and local legislative initiatives in favor of compassionate use'' (Grant, 2005). State legislation establishing the CMCR called for high quality medical research that would ''enhance understanding of the efficacy and adverse effects of marijuana as a pharmacological agent,'' but stressed the project ''should not be construed as encouraging or sanctioning the social or recreational use of marijuana.'' The CMCR funded many of the published studies on marijuana's potential use for treating multiple sclerosis, neuropathic pain, appetite suppression and cachexia. However, aside from the data produced by CMCR, no state-level medical marijuana laws have produced scientific data on marijuana's safety and effectiveness.

FDA approves medical use of a drug following a submission and review of an NDA or BLA. The FDA has not approved any drug product containing marijuana for marketing. Even so, results of small clinical exploratory studies have been published in the current medical literature. Many studies describe human research with marijuana in the United States under FDA-regulated IND applications.

However, FDA approval of an NDA is not the only means through which a drug can have a currently accepted medical use in treatment in the United States. In general, a drug may have a ''currently accepted medical use'' in treatment in the United States if the drug meets a five-part test. Established case law (Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131, 1135 (D.C. Cir. 1994)) upheld the Administrator of DEA's application of the five-part test to determine whether a drug has a ''currently accepted medical use.'' The following describes the five elements that characterize ''currently accepted medical use'' for a drug[10]:

i. the drug's chemistry must be known and reproducible

''The substance's chemistry must be scientifically established to permit it to be reproduced into dosages which can be standardized. The listing of the substance in a current edition of one of the official compendia, as defined by section 201 G) of the Food, Drug and Cosmetic Act, 21 U.S.C. 321G), is sufficient to meet this requirement.''

ii. there must be adequate safety studies

''There must be adequate pharmacological and toxicological studies, done by all methods reasonably applicable, on the basis of which it could fairly and responsibly be concluded, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, that the substance is safe for treating a specific, recognized disorder.''

iii. there must be adequate and well- controlled studies proving efficacy

''There must be adequate, well- controlled, well-designed, well-conducted, and well-documented studies, including clinical investigations, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, on the basis of which it could be fairly and responsibly concluded by such experts that the substance will have the intended effect in treating a specific, recognized disorder.''

iv. the drug must be accepted by qualified experts

''The drug has a New Drug Application (NDA) approved by the Food and Drug Administration, pursuant to the Food, Drug and Cosmetic Act, 21 U.S.C. 355. Or, a consensus of the national community of experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, accepts the safety and effectiveness of the substance for use in treating a specific, recognized disorder. A material conflict of opinion among experts precludes a finding of consensus.'' and

v. the scientific evidence must be widely available

''In the absence of NDA approval, information concerning the chemistry, pharmacology, toxicology, and effectiveness of the substance must be reported, published, or otherwise widely available, in sufficient detail to permit experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, to fairly and responsibly conclude the substance is safe and effective for use in treating a specific, recognized disorder.''

Marijuana does not meet any of the five elements necessary for a drug to have a ''currently accepted medical use.''

Firstly, the chemistry of marijuana, as defined in the petition, is not reproducible in terms of creating a standardized dose. The petition defines marijuana as including all Cannabis cultivated strains. Different marijuana samples derived from various cultivated strains may have very different chemical constituents including delta9-THC and other cannabinoids (Appendino et al., 2011). As a consequence, marijuana products from different strains will have different safety, biological, pharmacological, and toxicological profiles. Thus, when considering all Cannabis strains together, because of the varying chemical constituents, reproducing consistent standardized doses is not possible. Additionally, smoking marijuana currently has not been shown to allow delivery of consistent and reproducible doses. However, if a specific Cannabis strain is grown and processed under strictly controlled conditions, the plant chemistry may be kept consistent enough to produce reproducible and standardized doses.

As to the second and third criteria; there are neither adequate safety studies nor adequate and well-controlled studies proving marijuana's efficacy. To support the petitioners' assertion that marijuana has accepted medical use, the petitioners cite the American Medical Association's (AMA) 2009 report entitled ''Use of Cannabis for Medicinal Purposes.'' The petitioners claim the AMA report is evidence the AMA accepts marijuana's safety and efficacy. However, the 2009 AMA report clarifies that the report ''should not be viewed as an endorsement of state-based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the same and current standards for a prescription drug product.[11]''

Currently, no published studies conducted with marijuana meet the criteria of an adequate and well-controlled efficacy study. The criteria for an adequate and well-controlled study for purposes of determining the safety and efficacy of a human drug are defined under the Code of Federal Regulations (CFR) in 21 CFR 314.126. In order to assess this element, FDA conducted a review of clinical studies published and available in the public domain before February, 2013. Studies were identified through a search of PubMed[12] for articles published from inception to February 2013, for randomized controlled trials using marijuana to assess marijuana's efficacy in any therapeutic indication. Additionally, the review included studies identified through a search of bibliographic references in relevant systematic reviews and identified studies presenting original research in any language. Selected studies needed to be placebo-controlled and double-blinded. Additionally, studies needed to encompass administered marijuana plant material. There was no requirement for any specific route of administration, nor any age limits on study subjects. Studies were excluded that used placebo marijuana supplemented by the addition of specific amounts of THC or other cannabinoids. Additionally, studies administering marijuana plant extracts were excluded.

The PubMed search yielded a total of 566 abstracts of scientific articles. Of these abstracts, a full-text review was conducted with 85 papers to assess eligibility. Of the studies identified through the search of the references and the 566 abstracts from the PubMed search, only 11 studies met all the criteria for selection (Abrams et al., 2007; Corey-Bloom et al., 2012; Crawford and Merritt, 1979; Ellis et al., 2009; Haney et al., 2005; Haney et al., 2007; Merritt et al., 1980; Tashkin et al., 1974; Ware et al., 2010; Wilsey et al., 2008; Wilsey et al., 2013). These 11 studies were published between 1974 and 2013. Ten of these studies were conducted in the United States and one study was conducted in Canada. The identified studies examine the effects of smoked and vaporized marijuana for the indications of chronic neuropathic pain, spasticity related to Multiple Sclerosis (MS), appetite stimulation in human immunodeficiency virus (HIV) patients, glaucoma, and asthma. All studies used adult subjects.

The 11 identified studies were individually evaluated to determine if they successfully meet accepted scientific standards. Specifically, they were evaluated on study design including subject selection criteria, sample size, blinding techniques, dosing paradigms, outcome measures, and the statistical analysis of the results. The analysis relied on published studies, thus information available about protocols, procedures, and results were limited to documents published and widely available in the public domain. The review found that all 11 studies that examined effects of inhaled marijuana do not currently prove efficacy of marijuana in any therapeutic indication based on a number of limitations in their study design; however, they may be considered proof of concept studies. Proof of concept studies provide preliminary evidence on a proposed hypothesis involving a drug's effect. For drugs under development, the effect often relates to a short-term clinical outcome being investigated. Proof of concept studies often serve as the link between preclinical studies and dose ranging clinical studies. Thus, proof of concept studies generally are not sufficient to prove efficacy of a drug because they provide only preliminary information about the effects of a drug.

In addition to the lack of published adequate and well-controlled efficacy studies proving efficacy, the criteria for adequate safety studies has also not been met. Importantly, in its discussion of the five-part test used to determine whether a drug has a ''currently accepted medical use,'' DEA said, ''No drug can be considered safe in the abstract. Safety has meaning only when judged against the intended use of the drug, its known effectiveness, its known and potential risks, the severity of the illness to be treated, and the availability of alternative remedies'' (57 FR 10504). When determining whether a drug product is safe and effective for any indication, FDA performs an extensive risk-benefit analysis to determine whether the risks posed by the drug product's side effects are outweighed by the drug product's potential benefits for a particular indication. Thus, contrary to the petitioner's assertion that marijuana has accepted safety, in the absence of an accepted therapeutic indication which can be weighed against marijuana's risks, marijuana does not satisfy the element for having adequate safety studies such that experts may conclude that it is safe for treating a specific, recognized disorder.

The fourth of the five elements for determining ''currently accepted medical use'' requires that the national community of experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, accepts the safety and effectiveness of the substance for use in treating a specific, recognized disorder. A material conflict of opinion among experts precludes a finding of consensus. Medical practitioners who are not experts in evaluating drugs are not qualified to determine whether a drug is generally recognized as safe and effective or meets NDA requirements (57 FR 10499-10505).

There is no evidence that there is a consensus among qualified experts that marijuana is safe and effective for use in treating a specific, recognized disorder. As discussed above, there are not adequate scientific studies that show marijuana is safe and effective in treating a specific, recognized disorder. In addition, there is no evidence that a consensus of qualified experts have accepted the safety and effectiveness of marijuana for use in treating a specific, recognized disorder. Although medical practitioners are not qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, we also note that the AMA's report, entitled ''Use of Cannabis for Medicinal Purposes,'' does not accept that marijuana currently has accepted medical use. Furthermore, based on the above definition of a ''qualified expert'', who is an individual qualified by scientific training and experience to evaluate the safety and effectiveness of a drug, state-level medical marijuana laws do not provide evidence of a consensus among qualified experts that marijuana is safe and effective for use in treating a specific, recognized disorder.

As to the fifth part of the test, which requires that information concerning the chemistry, pharmacology, toxicology, and effectiveness of marijuana to be reported in sufficient detail, the scientific evidence regarding all of these aspects is not available in sufficient detail to allow adequate scientific scrutiny. Specifically, the scientific evidence regarding marijuana's chemistry in terms of a specific Cannabis strain that could produce standardized and reproducible doses is not currently available.

Alternately, a drug can be considered to have a ''currently accepted medical use with severe restrictions'' (21 U.S.C. 812(b)(2)(B)), as allowed under the stipulations for a Schedule II drug. Yet, as stated above, currently marijuana does not have any accepted medical use, even under conditions where its use is severely restricted.

In conclusion, to date, research on marijuana's medical use has not progressed to the point where marijuana is considered to have a ''currently accepted medical use'' or a ''currently accepted medical use with severe restrictions.''

- - - - - - - - - -

[9] In this quotation the term cannabis is interchangeable with marijuana.

[10] 57 FR I 0499, 10504–06 (March 26, 1992).

[11] In this quotation the term cannabis is used interchangeably for marijuana.

[12] The following search strategy was used, ‘‘(cannabis OR marijuana) AND (therapeutic use OR therapy) AND (RCT OR randomized controlled trial OR ‘‘systematic review’’ OR clinical trial OR clinical trials) NOT (‘‘marijuana abuse’’[Mesh] OR addictive behavior OR substance related disorders).’’

nolu chan  posted on  2016-09-06   18:27:48 ET  Reply   Trace   Private Reply  


TopPage UpFull ThreadPage DownBottom/Latest

[Home]  [Headlines]  [Latest Articles]  [Latest Comments]  [Post]  [Mail]  [Sign-in]  [Setup]  [Help]  [Register] 

Please report web page problems, questions and comments to webmaster@libertysflame.com